IMPACT Therapeutics Raises HK$119.50 Million via Full Exercise of 15% Over-Allotment Option

Bulletin Express06-05

IMPACT Therapeutics, Inc. announced that the overall coordinators have fully exercised the 15% over-allotment option linked to the company’s recent Hong Kong IPO. An additional 6.30 million H shares will be issued at HK$20.10 per share—the same price as the initial offering—generating net proceeds of approximately HK$119.50 million after fees and expenses.

Following the exercise, total issued share capital will rise to 282.46 million shares, up from 276.17 million. Of this, public H-share float will expand from 41.98 million shares (15.20% of total share capital) to 48.27 million shares (17.09%), while the 234.19 million converted H shares remain unchanged. The transaction keeps the company in compliance with the Hong Kong Stock Exchange’s public-float requirement.

The newly issued over-allotment shares are slated to begin trading on the Main Board of the Stock Exchange at 9:00 a.m. on 10 June 2026.

Management stated that the incremental proceeds will be allocated on a pro-rata basis according to the “Future Plans and Use of Proceeds” outlined in the IPO prospectus.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1199847182?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-05 21:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1199847182","market":"us","top_or_hot":-1,"title":"IMPACT Therapeutics Raises HK$119.50 Million via Full Exercise of 15% Over-Allotment Option","media":"Bulletin Express","content":"<p>IMPACT Therapeutics, Inc. announced that the overall coordinators have fully exercised the 15% over-allotment option linked to the company’s recent Hong Kong IPO. An additional 6.30 million H shares will be issued at HK$20.10 per share—the same price as the initial offering—generating net proceeds of approximately HK$119.50 million after fees and expenses.</p>\n<p>Following the exercise, total issued share capital will rise to 282.46 million shares, up from 276.17 million. Of this, public H-share float will expand from 41.98 million shares (15.20% of total share capital) to 48.27 million shares (17.09%), while the 234.19 million converted H shares remain unchanged. The transaction keeps the company in compliance with the Hong Kong Stock Exchange’s public-float requirement.</p>\n<p>The newly issued over-allotment shares are slated to begin trading on the Main Board of the Stock Exchange at 9:00 a.m. on 10 June 2026.</p>\n<p>Management stated that the incremental proceeds will be allocated on a pro-rata basis according to the “Future Plans and Use of Proceeds” outlined in the IPO prospectus.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IMPACT Therapeutics Raises HK$119.50 Million via Full Exercise of 15% Over-Allotment Option</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIMPACT Therapeutics Raises HK$119.50 Million via Full Exercise of 15% Over-Allotment Option\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-05 21:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>IMPACT Therapeutics, Inc. announced that the overall coordinators have fully exercised the 15% over-allotment option linked to the company’s recent Hong Kong IPO. An additional 6.30 million H shares will be issued at HK$20.10 per share—the same price as the initial offering—generating net proceeds of approximately HK$119.50 million after fees and expenses.</p>\n<p>Following the exercise, total issued share capital will rise to 282.46 million shares, up from 276.17 million. Of this, public H-share float will expand from 41.98 million shares (15.20% of total share capital) to 48.27 million shares (17.09%), while the 234.19 million converted H shares remain unchanged. The transaction keeps the company in compliance with the Hong Kong Stock Exchange’s public-float requirement.</p>\n<p>The newly issued over-allotment shares are slated to begin trading on the Main Board of the Stock Exchange at 9:00 a.m. on 10 June 2026.</p>\n<p>Management stated that the incremental proceeds will be allocated on a pro-rata basis according to the “Future Plans and Use of Proceeds” outlined in the IPO prospectus.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"07630","symbol_name":"英派药业-B","start_time":0,"source_url":"","article_id":"1199847182","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1199847182","pubTimestamp":1780664606,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"IMPACT Therapeutics, Inc. announced that the overall coordinators have fully exercised the 15% over-allotment option linked to the company’s recent Hong Kong IPO. An additional 6.30 million H shares...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"07630":"英派药业-B"},"translate_title":"IMPACT Therapeutics透过全数行使15%超额配股权集资11950万港元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"07630":1},"content_text":"IMPACT Therapeutics, Inc. announced that the overall coordinators have fully exercised the 15% over-allotment option linked to the company’s recent Hong Kong IPO. An additional 6.30 million H shares will be issued at HK$20.10 per share—the same price as the initial offering—generating net proceeds of approximately HK$119.50 million after fees and expenses.\nFollowing the exercise, total issued share capital will rise to 282.46 million shares, up from 276.17 million. Of this, public H-share float will expand from 41.98 million shares (15.20% of total share capital) to 48.27 million shares (17.09%), while the 234.19 million converted H shares remain unchanged. The transaction keeps the company in compliance with the Hong Kong Stock Exchange’s public-float requirement.\nThe newly issued over-allotment shares are slated to begin trading on the Main Board of the Stock Exchange at 9:00 a.m. on 10 June 2026.\nManagement stated that the incremental proceeds will be allocated on a pro-rata basis according to the “Future Plans and Use of Proceeds” outlined in the IPO prospectus.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1199847182","isCrawlerRequest":true}